Intra-Cellular Therapies (NASDAQ:ITCI) Research Coverage Started at StockNews.com

StockNews.com initiated coverage on shares of Intra-Cellular Therapies (NASDAQ:ITCI) in a research note published on Sunday morning. The firm issued a hold rating on the biopharmaceutical company’s stock.

Other equities analysts have also recently issued reports about the company. Leerink Partnrs cut Intra-Cellular Therapies from a “strong-buy” rating to a “hold” rating in a research note on Monday, January 13th. Royal Bank of Canada reissued a “sector perform” rating and set a $132.00 price objective (up from $108.00) on shares of Intra-Cellular Therapies in a research report on Wednesday, January 22nd. Cantor Fitzgerald raised shares of Intra-Cellular Therapies from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, January 14th. Canaccord Genuity Group lowered shares of Intra-Cellular Therapies from a “buy” rating to a “hold” rating and raised their price objective for the stock from $119.00 to $132.00 in a report on Friday, January 31st. Finally, JPMorgan Chase & Co. upped their target price on Intra-Cellular Therapies from $81.00 to $89.00 and gave the stock an “overweight” rating in a report on Monday, November 4th. Nine analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, Intra-Cellular Therapies currently has a consensus rating of “Moderate Buy” and an average target price of $103.62.

Intra-Cellular Therapies Price Performance

NASDAQ ITCI opened at $127.96 on Friday. Intra-Cellular Therapies has a 1 year low of $62.78 and a 1 year high of $128.19. The stock has a market capitalization of $13.60 billion, a PE ratio of -147.08 and a beta of 0.72. The business’s 50-day moving average is $106.66 and its 200 day moving average is $88.38.

Insider Activity at Intra-Cellular Therapies

In other news, CEO Sharon Mates sold 51,000 shares of the stock in a transaction that occurred on Wednesday, December 4th. The stock was sold at an average price of $85.80, for a total transaction of $4,375,800.00. Following the transaction, the chief executive officer now owns 1,070,329 shares in the company, valued at $91,834,228.20. This trade represents a 4.55 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Company insiders own 2.60% of the company’s stock.

Hedge Funds Weigh In On Intra-Cellular Therapies

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Accredited Wealth Management LLC acquired a new stake in Intra-Cellular Therapies during the fourth quarter worth about $28,000. True Wealth Design LLC purchased a new stake in shares of Intra-Cellular Therapies in the 3rd quarter valued at approximately $32,000. GAMMA Investing LLC increased its holdings in shares of Intra-Cellular Therapies by 46.3% during the 4th quarter. GAMMA Investing LLC now owns 758 shares of the biopharmaceutical company’s stock worth $63,000 after buying an additional 240 shares during the last quarter. Capital Performance Advisors LLP purchased a new stake in shares of Intra-Cellular Therapies during the 3rd quarter valued at approximately $74,000. Finally, Venturi Wealth Management LLC acquired a new position in Intra-Cellular Therapies in the fourth quarter valued at approximately $96,000. 92.33% of the stock is currently owned by institutional investors and hedge funds.

Intra-Cellular Therapies Company Profile

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.